## PAGE 1/33 \* RCVD AT 6/1/3/2006 9:10:04 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-6/27 \* DNIS:2738300 \* CSID:650 855 5322 \* DURATION (mm-ss): 15-56

Approved for use through 07/31/2006, OM8 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unitoss it contains a valid OMB control number.

To:

Art Unit: 1625 (Robert J. Balls)

CENTRAL FAX BENTER

Fax Number: 571-273-8300

JUN 1 3 2006

From:

Robert C. Hall, Reg. No. 39209

Roche Palo Alto LLC,

3431 Hillview Ave., Palo Alto, CA, Fax No.: 650/ 855-5322

**Total Pages:** 37

## Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on June 13, 2006.

(Date)

Signature

Robert C. Hall, Reg. No. 39,209

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

### **Documents Attached:**

Re. S/N 10/722,703, filed November 11, 2003, inventor Chen et al., Docket R0085D-CON

1. Amendment (37 CFR §1.111)

(08 pages)

2. Foster et al., "Potential of p38 Inhibitors...", Drug News Perspect.

(10 pages)

3. Badger et al., "Disease-Modifying Activity of SB 242235 ...", Arth. & Rheum.

(09 pages)

4. Lee et al., "p38 Mitogen-Activated Protein Kinase Inhibitors ...", Pharamacol.

(09 pages)

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gethering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Docs No. 126151v1

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

# PAGE 2/33 \* RCVD AT 6/13/2006 9:10:04 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-6/27 \* DVIS:2738300 \* CSID:650 855 5322 \* DVIRATION (mm-ss):15-56

Amendment

USSN: 10/722,703

Attorney Docket R0085D CON

PATENT Attorncy Docket No.: R0085D-CON

## CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being transmitted via facsimle to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450, at (571) 273-8300, on the date indicated below.

Name of Person Transmitting Robert C. Hall

Signature:

Date: June 13

- Koocii C. Hali

REGEIVED CENTRAL FAX GENTER

JUN 1 3 2006

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	First Named Inventor	Jian Chen et al.
<u>AMENDMENT</u>	Application Number	10/722,703
37 C.F.R. § 1.111	Confirmation Number	7431
	Filing Date	November 25, 2003
	Group Art Unit	1625
Address to:	Examiner	Balls, Robert J.
Mail Stop: Patent Application	Attorney Docket No.	R0085D CON
Commissioner for Patents	Title	6-Substituted Pyrido-
P.O. Box 1450		Pyrimidines
Alexandria, VA 22313-1450		

### AMENDMENT (37 C.F.R. § 1.111)

Sir:

This Amendment is responsive to the Office Action mailed on March 14, 2006, for which a three month statutory period was set for reply.

R0085D CON

**P20 822 2355**